In a tense parliamentary hearing on December 2, Fair Trading Commission (FTC) Executive Director Bevan Narinesingh faced rigorous interrogation from Public Administration and Appropriations Committee (PAAC) Chairman Jagdeo Singh regarding the commission’s perceived inaction on potential anti-competitive practices within the pharmaceutical industry.
Speaker Singh, visibly frustrated throughout the proceedings, challenged Narinesingh on what he characterized as the FTC’s ‘lethargic’ response to serious allegations of monopolistic behavior in drug supply and distribution. The confrontation centered on the commission’s failure to utilize its statutory powers under the Fair Trading Act despite receiving formal complaints and documentation since September 2024.
Singh methodically outlined the FTC’s broad investigative authority, particularly emphasizing Section 9 provisions that empower the commission to act on its own initiative without requiring formal complaints. ‘Anti-competitive behavior in a marketplace is among the highest public-interest concerns needing protection,’ Singh asserted, receiving agreement from Narinesingh before pressing further on the commission’s inaction.
The hearing revealed that despite a September 6, 2024 letter from a private business association raising competition concerns, the FTC’s response consisted primarily of information requests rather than initiating formal investigations. Singh questioned why the commission hadn’t invoked Section 8 powers to compel document production from suspected entities instead of placing the burden on complainants to obtain sensitive corporate records.
Narinesingh defended the FTC’s approach, citing ongoing evidence gathering through meetings with Health Ministry officials in December 2024 and consultations with the Pharmacy Board. However, when pressed for documentation of these meetings, he could not immediately produce minutes or formal reports.
The exchange intensified when Singh referenced the FTC’s December 13, 2024 public statement acknowledging that concerns ‘may require further examination.’ The chairman demanded concrete actions beyond letter-writing and meetings, to which Narinesingh cited public notices inviting input through digital channels.
A critical moment emerged when Narinesingh revealed the FTC had determined ‘sufficient grounds’ for investigation by June 17, 2025 but claimed inability to proceed due to the commission’s board being dissolved since May. Singh challenged this justification, questioning where the Fair Trading Act circumscribes the executive director’s authority based on board availability.
The session concluded with Singh issuing comprehensive directives for the FTC to provide all relevant documentation, including internal communications, meeting minutes, and task assignments, before adjourning until January 26 for further review.